Source: BioPortfolio

BlackThorn: BlackThorn Therapeutics Announces Positive Phase 1 Results for Its Selective KOR Antagonist BTRX335140

Phase 1 results and new translational data supporting the development of BTRX335140 for neurobehavioral disorders presented at the Kappa Therapeutics 2019 Conference BlackThorn Therapeutics a neurobehavioral health company ...

Read full article »
BlackThorn's Competitors | BlackThorn's News | BlackThorn's Financials
Stay up-to-date with the latest news on BlackThorn
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
William J Martin's photo - President & CEO of BlackThorn

President & CEO

William J Martin

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on BlackThorn